Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic nucleoside analog structurally related to tubercidin. It consists of a pyrrolopyrimidine base substituted with an iodine atom at the 5-position and attached to a deoxyribose sugar. Its primary mechanism of action is as an inhibitor of adenosine kinase. By inhibiting this enzyme—which phosphorylates adenosine to AMP—the compound can modulate cellular adenosine levels and affect purine metabolism. It has been studied experimentally but has not reached clinical development or approval for any indication[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine.